Tag: Bright Minds Biosciences - Psychedelic Alpha

Introducing Pα+: learn more and subscribe today.

Read more about the article Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Post published:August 8, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Post published:July 20, 2023
Post category:Press Release

Read more about the article Bright Minds Announces Effective Date of Share Consolidation

Bright Minds Announces Effective Date of Share Consolidation

Post published:July 11, 2023
Post category:Press Release

Read more about the article Bright Minds Announces Proposed Share Consolidation

Bright Minds Announces Proposed Share Consolidation

Post published:June 22, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Post published:April 19, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Post published:April 10, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Post published:February 27, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Non-Executive Director Appointment

Bright Minds Biosciences Announces Non-Executive Director Appointment

Post published:February 17, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Post published:February 8, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Post published:January 28, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.